Aplisens S.A. carries a market capitalization of 204.89M, placing it among publicly traded companies globally. Its enterprise value stands at 155.99M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 204.89M |
| Enterprise Value | 155.99M |
Aplisens S.A. currently has 11.14M shares outstanding.
| Shares Outstanding | 11.14M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Aplisens S.A. trades at a trailing price-to-earnings ratio of 12.29. The price-to-sales ratio is 1.27, and the price-to-book ratio stands at 0.89.
| PE Ratio | 12.29 |
| PS Ratio | 1.27 |
| PB Ratio | 0.89 |
| P/TBV Ratio | 0.88 |
| P/FCF Ratio | 4.81 |
| P/OCF Ratio | 5.66 |
On an enterprise value basis, Aplisens S.A. trades at an EV/EBITDA multiple of 8.31 and an EV/FCF ratio of 3.99. The EV/Sales ratio of 1.06 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 8.31 provides insight into valuation relative to core operating earnings.
| EV / Sales | 1.06 |
| EV / EBITDA | 8.31 |
| EV / EBIT | 8.31 |
| EV / FCF | 3.99 |
Aplisens S.A. maintains a current ratio of 12.68, meaning it holds 12.7x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 12.68 |
| Quick Ratio | 3.36 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | 36.68 |
Aplisens S.A. posts a return on equity of 7.40 and a return on invested capital of 6.56.
| Return on Equity (ROE) | 7.40 |
| Return on Assets (ROA) | 6.10 |
| Return on Invested Capital (ROIC) | 6.56 |
| Return on Capital Employed (ROCE) | 7.08 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.29 |
Over the trailing twelve months, Aplisens S.A. has paid 3.37M in income taxes, reflecting an effective tax rate of 17.56.
| Income Tax | 3.37M |
| Effective Tax Rate | 17.56 |
Aplisens S.A.'s stock has declined approximately -2.6455% over the past 52 weeks. The 50-day moving average sits at 17.99, while the 200-day moving average is 17.85.
| Beta (5Y) | N/A |
| 52-Week Price Change | -2.6455% |
| 50-Day Moving Average | 17.99 |
| 200-Day Moving Average | 17.85 |
| Average Volume (20 Days) | N/A |
Over the trailing twelve months, Aplisens S.A. generated 146.51M in revenue and converted that into 15.16M in net income, yielding earnings per share of 1.49. EBITDA reached 18.78M, while operating income came in at 18.78M.
| Revenue | 146.51M |
| Gross Profit | 50.38M |
| Operating Income | 18.78M |
| Pretax Income | 19.20M |
| Net Income | 15.16M |
| EBITDA | 18.78M |
| EBIT | 18.78M |
| Earnings Per Share (EPS) | 1.49 |
Total book value stands at 208.55M, with working capital of 126.14M providing operational flexibility.
| Cash & Cash Equivalents | 36.34M |
| Total Debt | N/A |
| Net Debt | -16.72M |
| Equity (Book Value) | 208.55M |
| Book Value Per Share | 19.65 |
| Working Capital | 126.14M |
Aplisens S.A. produced 32.89M in operating cash flow over the past twelve months. After subtracting -5.80M in capital expenditures, free cash flow totaled 27.09M - equivalent to 2.55 per share.
| Operating Cash Flow | 32.89M |
| Capital Expenditures | -5.80M |
| Free Cash Flow | 27.09M |
| FCF Per Share | 2.55 |
Aplisens S.A. operates with a gross margin of 34.39, reflecting its pricing power and cost economics. The operating margin of 12.82 and net profit margin of 10.35 provide insight into operational efficiency.
| Gross Margin | 34.39 |
| Operating Margin | 12.82 |
| Pretax Margin | 13.10 |
| Profit Margin | 10.35 |
| EBITDA Margin | 12.82 |
The company's payout ratio of 47.26 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.73 |
| Dividend Yield | N/A |
| Payout Ratio | 47.26 |
| Shareholder Yield | 5.74 |
| FCF Yield | 20.77 |
Aplisens S.A.'s most recent stock split took place on April 19, 2016 with a 3:1 split ratio.
| Last Split Date | 4/19/2016 |
| Split Ratio | 3:1 |
Aplisens S.A. posts an Altman Z-Score of 11.37, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 11.37 |